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Abstract 
BACKGROUND: Keloid is an overactive condition of the skin tissue to early lesions characterised by proliferation 
of fibroblasts, excessive collagen production in the lesion. Treatment of keloids is a big challenge because of the 
poor response rate and high risk of recurrence after treatment. We found that bleomycin offers promise in the 
treatment of keloids.  
AIM: To evaluate the efficacy of bleomycin injected in the injury for keloids treatment.  
METHODS: The treatment was carried out in 55 patients having 120 keloids of different sizes and locations. 
Average treatments were 4 times.  
RESULTS: Complete flattening was 70.8%, highly significant flattening was 8.3%, no patient of minimal flattening. 
Systemic side-effects of bleomycin were not evaluated, but local side-effects were mainly pains (100%), blisters 
(78.3%), ulceration (5.8%), and hyperpigmentation (56.7%).  
CONCLUSION: The percentage of patients recurring 6, 12, 15, 18 months after the last treatment were 3.8, 15.4, 
45.5, 50%, respectively. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Keloid is an overactive condition of the skin 
tissue to early lesions characterised by proliferation of 
fibroblasts and excessive production of collagen in the 
lesion, with mechanisms not yet fully understood [1]. 
Areas most frequently affected are chest, shoulder, 
ear lobe. Keloid is usually itchy and painful [2]. 
Nowadays, therapy is a challenge although many 
treatments are recommended, without agreement on 
the effectiveness of different choice. Bleomycin-
induced apoptosis with sclerosing action on 
endothelial cells inhibited collagen synthesis by 
inhibiting the lysyl-oxidase enzyme and TGF-β, and it 
was used in keloid treatment for the first time by 
Bodokh and Brun in 1996 [3]. 
We aimed to evaluate the efficacy of 
bleomycin injected in the injury for keloids treatment. 
 
 
Methods 
 
A group of 55 patients with 120 studied scars 
were selected (aged from 15 to 70 years). Scar 
duration varies from several months to years, not 
been treated before, not ulcerated or infected. 
An injectable solution of bleomycin was 
prepared by diluting 15 units of bleomycin in 10 ml of 
sterile saline. The medication was injected into the 
mid-lesion in depth, 0.2-0.4 ml/cm
2
 (maximum volume 
per session 3.5 ml). The interval between injections 
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was 4 weeks, and the total number of treatment 
sessions depended on the cosmetic outcome of each 
lesion. Patients received chest X-ray before treatment 
every 3 months and 6 months after the last treatment. 
Evaluation of the treatment response is 
conducted by VSS (Vancouver Scar Scale). 
 
 
Results 
 
The average number of injections was 3.9 ± 
1.1. After treatment, 80.8% of patients got itchiness 
relief, and 73.3% of patients got pain relief. Blood 
vessel status, scar stiffness, and scar thickness 
improved at 70.6%, 89.3% and 87%, respectively, by 
the VSS scale. In particular: 70.8% of scars became 
completely flat, 8.3% fairly flat, 17.5% comparatively 
flat, 3.3% averagely flat and no poorly flat scars. 
Regarding undesirable effects, this study 
showed that 100% scar tissue lasted on average of 
3.6 ± 1.4, 94/120 scars accounted for 78.3% have 
blisters, with an average length of 4.5 ± 1.3; 5.8% of 
ulcer scars with an average length of 10.6 ± 1.3; 
Hyperpigmentation was frequently noted after therapy 
(56.7%) and much thicker and harder the scar was, 
more treatment times was needed, with stiffness 
improvement poorer than in the treatment of soft and 
thin ones. The condition of vascular, pigmentation, 
and scar location had no relationship to some 
treatment as well as the level of scar thickness 
improvement as presented in Table 1. 
Table 1: Efficacy of the treatment 
Variable Value 
VSS scores 
Before 
treatment 
After 
treatment 
p 
Vascularity    1.7 ± 1 0.5 ± 0.6 
< 0.05 
Pigmentation  0.2 ± 0.6     1.1 ± 1 
Pliability 2.8 ± 0.9 0.3 ± 0.5 
Height 2.3 ± 0.6 0.3 ± 0.5 
Functional Symptoms 
Pruritus 80.8% 
Pain  73.3% 
Scar thickness improvement 
The complete flattening  70.8% 
Highly significant flattening 8.3% 
Significant flattening 17.5% 
Moderate flattening 3.3% 
Minimal flattening 0% 
Local side-effect Lasting days 
Pain  120 (100%)   3.6 ± 1.4 
Swollen   26 (21.7%)   3.3 ± 1.2 
Blisters    94 (78.3%)   4.5 ± 1.3 
Ulceration      7 (5.8%) 10.6 ± 1.3 
Scaled  101 (84.1%) 13.6 ± 1.7 
Hyperpigmentation    68 (56.7%)  
Recurrence 
After 3 months (n = 32) 0 
After 6 months (n = 26) 1 (3.8%) 
After 12 months (n = 13) 2 (15.4% 
After 15 months (n = 11) 5 (45.5%) 
After 18 months (n = 6) 3 (50%) 
 
Due to many technical and financial 
constraints, our study did not measure bleomycin 
concentrations in the blood. However, in surveying 
complete blood count, liver and kidney function and 
chest X-ray, we did not record any systemic side 
effect. Local side effects were noted significantly, with 
100% scars with pain during treatment.  
 
 
Discussion 
 
We found that bleomycin improved vascular 
condition by 70.6% after treatment (mean VSS score 
from 1.7 ± 1 to 0.5 ± 0.6) and mean VSS of stiffness 
decreased by 89.3%. Some injections needed, itch 
and pain relief was similar to Saray et al., and S. 
Srivastava et al., studies [4], [5], [6]. 
The recurrence rate in our study was higher 
than in Saray (2005), with 14% of patients recurring 
after 18 months [4]. We found that the rate of 
recurrent scars in the thorax, the front of the 
breastbone was higher than in other surgical areas. 
The difference is statistically significant. In contrast, 
there was no relation between pre-treatment thickness 
and recurrence risk. 
In conclusion, bleomycin is a safe and 
effective method for treating keloids. However, the 
high rate of recurrence after treatment confirms the 
difficulty in the correct management of keloid scars. 
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